231 related articles for article (PubMed ID: 15684491)
1. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.
Kageyama M; Namiki H; Fukushima H; Ito Y; Shibata N; Takada K
Biol Pharm Bull; 2005 Feb; 28(2):316-22. PubMed ID: 15684491
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
3. Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats.
Kageyama M; Namiki H; Fukushima H; Terasaka S; Togawa T; Tanaka A; Ito Y; Shibata N; Takada K
Biol Pharm Bull; 2005 Jan; 28(1):130-7. PubMed ID: 15635177
[TBL] [Abstract][Full Text] [Related]
4. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
5. Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers.
Kageyama M; Fukushima K; Togawa T; Fujimoto K; Taki M; Nishimura A; Ito Y; Sugioka N; Shibata N; Takada K
Biol Pharm Bull; 2006 Apr; 29(4):779-84. PubMed ID: 16595917
[TBL] [Abstract][Full Text] [Related]
6. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers.
Salphati L; Benet LZ
Biochem Pharmacol; 1998 Feb; 55(4):387-95. PubMed ID: 9514072
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
[TBL] [Abstract][Full Text] [Related]
8. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
10. Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats.
Kishimoto W; Takano J; Senda C; Ishiguro N; Sakai K; Igarashi T
Biol Pharm Bull; 2000 Sep; 23(9):1027-32. PubMed ID: 10993198
[TBL] [Abstract][Full Text] [Related]
11. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats.
Zhang Y; Hsieh Y; Izumi T; Lin ET; Benet LZ
J Pharmacol Exp Ther; 1998 Oct; 287(1):246-52. PubMed ID: 9765344
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.
Hochman JH; Chiba M; Yamazaki M; Tang C; Lin JH
J Pharmacol Exp Ther; 2001 Jul; 298(1):323-30. PubMed ID: 11408558
[TBL] [Abstract][Full Text] [Related]
13. Dextran sulfate sodium-induced colitis and ginseng intervention altered oral pharmacokinetics of cyclosporine A in rats.
Yang Y; Hu N; Gao XJ; Li T; Yan ZX; Wang PP; Wei B; Li S; Zhang ZJ; Li SL; Yan R
J Ethnopharmacol; 2021 Jan; 265():113251. PubMed ID: 32810615
[TBL] [Abstract][Full Text] [Related]
14. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang L; Wring SA; Woolley JL; Brouwer KR; Serabjit-Singh C; Polli JW
Drug Metab Dispos; 2001 May; 29(5):754-60. PubMed ID: 11302944
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of factors to decrease bioavailability of cyclosporin A in rats with gentamicin-induced acute renal failure.
Shibata N; Inoue Y; Fukumoto K; Nishimura A; Fukushima K; Yoshikawa Y; Spiteller G; Takada K
Biol Pharm Bull; 2004 Mar; 27(3):384-91. PubMed ID: 14993807
[TBL] [Abstract][Full Text] [Related]
16. Investigation of aortic CYP3A bioactivation of nitroglycerin in vivo.
Yuan R; Sumi M; Benet LZ
J Pharmacol Exp Ther; 1997 Jun; 281(3):1499-505. PubMed ID: 9190888
[TBL] [Abstract][Full Text] [Related]
17. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
[TBL] [Abstract][Full Text] [Related]
18. Mdr1 limits CYP3A metabolism in vivo.
Lan LB; Dalton JT; Schuetz EG
Mol Pharmacol; 2000 Oct; 58(4):863-9. PubMed ID: 10999959
[TBL] [Abstract][Full Text] [Related]
19. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.
Takano M; Hasegawa R; Fukuda T; Yumoto R; Nagai J; Murakami T
Eur J Pharmacol; 1998 Oct; 358(3):289-94. PubMed ID: 9822896
[TBL] [Abstract][Full Text] [Related]
20. The xenobiotic inhibitor profile of cytochrome P4502C8.
Ong CE; Coulter S; Birkett DJ; Bhasker CR; Miners JO
Br J Clin Pharmacol; 2000 Dec; 50(6):573-80. PubMed ID: 11136296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
